Neko Health today announced the completion of its $700 million Series C funding round.
The round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with participation from existing investors Atomico, General Catalyst, and Lakestar, alongside new backers including Liberty City Ventures, Positive Sum, and BDT & MSD. The fundraise follows a $260 million Series B in January 2025.
Founded by Spotify's Daniel Ek and Hjalmar Nilsonne, Neko Health is a health technology company redefining how people understand and act on their health.
At the heart of Neko’s offering is the Neko Health Scan, a 60-minute, comprehensive, non-invasive, and radiation-free health assessment that captures millions of health data points, priced at £299 in the UK and 2,750 SEK in Sweden.
Using proprietary sensors alongside blood analysis, the scan assesses skin health, including moles and marks, biomarkers to identify pre-diabetes risk, as well as blood abnormalities and risk factors linked to metabolic syndrome, stroke, and heart attack. Results are delivered on-site within minutes and discussed during an in-person consultation with a medical professional, providing members with personalised and actionable health findings.
